HHS' Adm. Brett Giroir expounds on national COVID testing strategy at AACC
Skip to main content
MDHC_Logotype_white
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • This Week's News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • People
    • Regional News
    • Digital Edition
    •  Alan B. Miller
      Looking ahead with optimism as we continue to transform healthcare
      Cable news and the gender gap
      An older man wearing a mask receiving a vaccine.
      Want more diversity in clinical trials? Start with the researchers
      Two travel nurses wearing personal protective equipment.
      Healthcare providers face high costs, demand for agency staff as COVID-19 rages
    • An older man wearing a mask receiving a vaccine.
      Want more diversity in clinical trials? Start with the researchers
      A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
      Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
      Two travel nurses wearing personal protective equipment.
      Healthcare providers face high costs, demand for agency staff as COVID-19 rages
    • Health suffers as rural hospitals close
      Medicare ACO participants fell in 2021
      Louisiana gets reports vaccine providers are discriminating
      'We know this is real': New clinics aid virus 'long-haulers'
    • Last-minute COVID costs cut into UnitedHealthcare's $396 million operating income
      CMS approves rule forcing insurers to ease prior authorization
      COVID-19 still a big uncertainty for insurers in 2021
      Health insurers' outlook boosted after Dems' Georgia win
    • It's a secret: California keeps key virus data from public
      lacewell_linda_supertinendent_dept_of_financial_services_8.47.jpg
      New York state investigates drug price spikes during pandemic
      Health experts blame rapid expansion for vaccine shortages
      HHS freezes rule targeting community health centers' drug discounts
    • By the Numbers: 20 largest healthcare investment banks in 2020
      Providers await new HHS coronavirus grant reporting deadline
      Operation Warp Speed Dr. Moncef Slaoui, Pfizer Group President Angela Hwang, Moderna CEO Stephane Bancel, CVS Health Executive Vice President Karen Lynch and McKesson CEO Brian Tyler participate in a panel discussion on the COVID-19 vaccine.
      Hospitals, drug companies strive to stand out virtually at JPM
      Intermountain, Trinity, Memorial Hermann behind $300M private equity fund
    • Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years - Transcript
      A man in a room with servers.
      Momentum grows to outsource hospital tech functions in 2021
      5 things to know about Google's $2.1B Fitbit acquisition
    • An older man wearing a mask receiving a vaccine.
      Want more diversity in clinical trials? Start with the researchers
      Avocado
      Avocado a day keeps the doctor away
      50% of Americans make resolutions. Fewer than 27% keep them over time.
      Data Points: Sticking with your resolutions
      U.K. chief scientist says new virus variant may be more deadly
    • Cerner names Erceg as new CFO
      Elizabeth Richter will serve as acting CMS administrator
      Providence names new chief financial officer
      Wisconsin's top health official departing for federal job
    • Midwest
    • Northeast
    • South
    • West
  • Insights
    • ACA 10 Years After
    • Best Practices
    • InDepth Special Reports
    • Innovations
    • The Affordable Care Act after 10 years
    • New care model helps primary-care practices treat obesity
      doctor with patient
      COVID-19 treatment protocol developed in the field helps patients recover
      Rachel Wyatt
      Project to curb pressure injuries in hospitals shows promise
      Yale New Haven's COVID-19 nurse-staffing model has long-term benefits
    • Modern Healthcare InDepth: Breaking the bias that impedes better healthcare
      Videos: Healthcare industry executives describe their encounters with racism
      Michellene Davis
      Healthcare leadership lacks the racial diversity needed to reduce health disparities
      Dr. James Hildreth
      How medical education can help fight racism
      Quotes from rebadged employees
      Outsourcing IT, revenue cycle takes toll on internal culture
    • A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
      A woman with a wearable sensor talking to her provider.
      Wearable sensors help diagnose heart rhythm problems in West Virginia
      self service station
      COVID-19 pushes patient expectations toward self-service
      Targeting high-risk cancer patients with genetics
  • Transformation
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Highmark Health inks six-year cloud, tech deal with Google
      Study: 1 in 5 patients report discrimination when getting healthcare
      HHS proposes changing HIPAA privacy rules
      Android health records app launches at 230 health systems
    • California hospitals prepare ethical protocol to prioritize lifesaving care
      Amazon, JPMorgan Chase, Berkshire Hathaway disband Haven
      Digital pathways poised to reshape healthcare continuum in 2021
      Healthcare was the hardest hit by supply shortages across all U.S. industries
    • A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
      A woman with a wearable sensor talking to her provider.
      Wearable sensors help diagnose heart rhythm problems in West Virginia
      New care model helps primary-care practices treat obesity
      How hospitals are building on COVID-19 telehealth momentum
    • Regional insurers bet big on virtual-first plans
      MedPAC votes to boost hospital payments, freeze or cut other providers
      Most Next Gen ACOs achieved bonuses in 2019
      Congress recalibrates Medicare Physician Fee Schedule after lobbying
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
    • Health Systems Financials
      Executive Compensation
      Physician Compensation
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
    • Wellstar CEO calls adapting for the pandemic her bold move
      Howard P. Kern
      Recognizing the value of telehealth in its infancy
      Dr. Stephen Markovich
      A bold move helped take him from family doctor to OhioHealth CEO
      Dr. Bruce Siegel
      Why taking a hospital not-for-profit was Dr. Bruce Siegel’s boldest move
    • Barry Ostrowsky
      Ending racism is a journey taken together; the starting point must be now
      Laura Lee Hall and Gary Puckrein
      Increased flu vaccination has never been more important for communities of color
      John Daniels Jr.
      Health equity: Making the journey from buzzword to reality
      Mark C. Clement and David Cook
      We all need to 'do something' to fight inequities and get healthcare right, for every patient, every time
    •  Alan B. Miller
      Looking ahead with optimism as we continue to transform healthcare
      Dr. Bruce Siegel
      By protecting the healthcare safety net, Biden can put us on the path to a stronger country
      Healing healthcare: some ideas for triage by the new Congress, administration
      Dr. Sachin H. Jain
      Medicare for All? The better route to universal coverage would be Medicare Advantage for All
    • Letters: Eliminating bias in healthcare needs to be ‘deliberate and organic’
      Letters: Maybe dropping out of ACOs is a good thing for patients
      Letters: White House and Congress share blame for lack of national COVID strategy
      Letters: VA making strides to improve state veterans home inspections
    • Sponsored Content Provided By Optum
      How blockchain could ease frustration with the payment process
      Sponsored Content Provided By Optum
      Three steps to better data-sharing for payer and provider CIOs
      Sponsored Content Provided By Optum
      Reduce total cost of care: 6 reasons why providers and payers should tackle the challenge together
      Sponsored Content Provided By Optum
      Why CIOs went from back-office operators to mission-critical innovators
  • Awards
    • Award Programs
    • Nominate
    • Previous Award Programs
    • Other Award Programs
    • Best Places to Work in Healthcare Logo for Navigation
      Nominations Open - Best Places to Work in Healthcare
      Nominations Open - Health Care Hall of Fame
      Nominations Open - 50 Most Influential Clinical Executives
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Top 25 Minority Leaders
    • Top 25 Women Leaders
    • Excellence in Nursing Awards
    • Design Awards
    • Top 25 COOs in Healthcare
    • 100 Top Hospitals
    • ACHE Awards
  • Events
    • Conferences
    • Galas
    • Webinars
    • COVID-19 Event Tracker
    • Leadership Symposium
    • Healthcare Transformation Summit
    • Women Leaders in Healthcare Conference
    • Workplace of the Future Conference
    • Strategic Marketing Conference
    • Social Determinants of Health Symposium
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Minority Leaders Gala (2022)
    • Top 25 Women Leaders Gala
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
    • Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next 4 years
      Carter Dredge
      Next Up Podcast: Ready, set, innovate! Innovation and disruption in healthcare
      Next Up Podcast: COVID-19, social determinants highlight health inequities — what next?
      Ceci Connolly
      Next Up Podcast: How to navigate the murky post-election waters
    • Beyond the Byline: Regulators aim to boost value push with fraud and abuse law updates
      An older man wearing a mask receiving a vaccine.
      Beyond the Byline: Verifying information on the chaotic COVID-19 vaccine rollout
      doctor burnout
      Beyond the Byline: How healthcare supply chain struggles contribute to employee burnout
      Beyond the Byline: Covering race and diversity in the healthcare industry
    • Leading intention promote diversity and inclusion
      Introducing Healthcare Insider Podcast
    • The Check Up: Chip Kahn
      The Check Up: Chip Kahn of the Federation of American Hospitals
      The Check Up: Trenda Ray
      The Check Up: Trenda Ray of the University of Arkansas for Medical Sciences
      The Check Up: Dr. Kenneth Davis
      The Check Up: Dr. Kenneth Davis of Mount Sinai Health System
      The Check Up: Dr. Thomas McGinn
      The Check Up: Dr. Thomas McGinn of CommonSpirit Health
    • Video: Ivana Naeymi Rad of Intelligent Medical Objects
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Safety & Quality
December 16, 2020 01:22 PM

HHS' Adm. Brett Giroir expounds on national COVID testing strategy at AACC

Madeleine Johnson, 360Dx
  • Tweet
  • Share
  • Share
  • Email
  • More
    Print
    Modern Healthcare Illustration / Getty Images

    Adm. Brett Giroir, the coordinator of the US COVID-19 testing efforts for HHS addressed attendees of the American Association of Clinical Chemistry Laboratory Expo — held virtually this year due to the pandemic — in a special session on Tuesday evening, expounding on federal efforts to stimulate COVID-19 test development, maintain the supply chain, and coordinate with manufacturers and labs.

    Giroir, the US assistant secretary of health, thanked laboratorians, who he said had performed 216 million tests as of Tuesday, for their efforts during the pandemic. "You have been on the front line, you are saving people every day. I wish I could give a medal to all of you but for now at least you'll have the sincerest thanks," he said.

    The current testing problems in the US are not due to lack of efforts, Giroir said, or due to a lack of funding. "I want to absolutely assure you that money is not an issue," he said, but rather the problem is due to "physical limitations."

    The SARS-CoV-2 virus has hallmarks that make it challenging to contain, Giroir said. Peak viral loads in asymptomatic people — who make up as many as 90 percent of infections in young, healthy people, he said — are typically as high as in those with symptoms. And, there are indications that peak viral load can actually precede symptoms.

    "This is something that we could never have imagined in March or even April, that this virus would be so insidious, which leads it to being so pervasive," Giroir said. The characteristics mean a strategy of testing symptomatic people followed by tracing and quarantining contacts will likely be ineffective except in certain workplaces or group living conditions.

    To stimulate testing capacity, the US has invested approximately $4.5 billon so far, Giroir said, and has tried to shore up the supply chain. For example, Giroir cited 38 so-called "air bridge" flights, which involved transporting foreign-manufactured supplies via US military aircraft rather than shipping them by boat. Ten of these flights alone were to bring pipette tips, he said. 

    Among the technical principles underlying the national testing strategy, Giroir said that increasing the diversity of tests and platforms is very important.

    "This really has to be a layered system," he said, calling in particular Hologic's Panther platform "a great instrument, but they have very tight limitations on supplies, very few places have it, and every nursing home doesn't have a Panther, nor does every school." He noted that Hologic received funding to increase manufacturing months ago, but that process takes time, and he expects to see results early next year. 

    Regarding testing diversity, Giroir called out point-of-care rapid tests, highlighting the Emergency Use Authorization from the US Food and Drug Administration for the first over-the-counter test on Tuesday — the Ellume COVID-19 Home Test from Australian digital diagnostics firm Ellume — and noted that he anticipates another prescription-use-only home-use test to get EUA shortly.

    "We've really tried to target innovation to achieve capacity and diversity," Giroir said. This was done while co-evolving regulations and guidance at the FDA, the Centers for Medicare and Medicaid Services, and the US Centers for Disease Control and Prevention, he said.

    Another principle to the national strategy has been to expand the industrial base and understand the interdependencies in the supply chain.

    When the pandemic began, "The US supply chain was a wreck, there was no US supply chain, there wasn't even an approach to the US supply chain, There was nothing in the stockpile," he said. "I don't think that will ever happen again, as we understand that diagnostics and testing are a core part of our strategy. We have to be better prepared in the next decade than we were in the past decade."

    Giroir reviewed the testing innovation and research and development promotion in the US, highlighting programs like the US Department of Defense's Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative, and HHS' Biomedical Advanced Research and Development Authority (BARDA), as well as programs supporting scale-up and implementation, like the Defense Production Act. As an example, Giroir said the newly authorized OTC Ellume test was initially supported by the NIH, then scaled with support from RADx-Tech, and "it is now subject to potential funding through some of our scaling programs with the Department of Defense," he said.

    Giroir also reviewed the evolution of the US testing capacity. In May, the EUA testing capacity was 33 million tests per month, including 12 million "all-in-one" lab-based molecular tests, 19 million open platform tests, 2 million point-of-care molecular tests, and 1 million point-of-care antigen tests, not including pooling approaches.

    As of this month, the capacity has reached 183 million tests per month. Although lab-based open platform testing capacity has more than doubled, almost all of the growth was attributable to a POC antigen test capacity growth to 111 million. 

    "The kinds of all-in-one laboratory tests that you love don't scale well," Giroir concluded. "There is not enough money on the planet – nor injected molding facilities, nor complex chemistries – to provide you all the Roche and Panther [systems] that you want. Same thing with Cepheid," he said.

    "That is not a fault of the administration, nor of the companies, it's just that these have been developed over years so that they cannot be copied by China and other places, so they are very difficult to scale," Giroir also said.

    Nevertheless, he noted that the US government has "put hundreds of millions of dollars into scaling them," and said that labs should expect to see the results in the next year.

    "But the clear winner is point of care," he said. "That's where the scale is, that's where the growth areas are, and there are technical reasons for that."

    Antigen and rapid molecular tests may not be as sensitive or specific as lab-based molecular tests, but Giroir also said that PCR is perhaps not the ideal test in all situations.

    "Let me be super provocative here by saying that nucleic acid amplification technologies are imperfect and a biased gold standard," he said. "I think it has served us all poorly to create the myth that it is a gold standard; it is a gold standard in a certain part of the ecosystem, but not in all parts," he added, noting that PCR tests are "poor predictors of contagiousness" while rapid antigen tests have similar levels of false positives, with repeat antigen testing outperforming PCR testing for outbreak control in part due to differences in turnaround times.

    "I think point-of-care testing will gain significant market share as we move forward ... particularly over the counter," Giroir said.

    Among the many points he touched on, Giroir noted that his team has aided state governors with their preparedness plans, including through federal procurement and distribution for things like swabs and media.

    Additionally, "We've tried to support the commercial market to align distribution, so every month with Cepheid, with Hologic, with Roche, we look at the distribution of machines, the reliance of the community on that machine, and what the tests are on that and try to get some alignment knowing that nobody is going to get as much Cepheid GeneXperts as they want, nobody is going to get as much Hologic as they want, [but there are] lots of Thermo Fisher [Scientific systems] to go around, lots of other platforms," he said.

    The federal coordination effort also tries to respond to urgent requests, Giroir said, but "the problem right now is the whole country is an urgent request and it's impossible to meet every need."

    Some federal efforts are producing results. There are now 297 tests with EUA, and Giroir noted that the 216 million tests performed in the US as of Tuesday didn't include 40 million point-of-care tests that have not been reported.

    In terms of results of the national strategy, Giroir highlighted that the states were supplied with $11 billion in testing funding in May and $9 billion has not been spent. There has also been $20 billion spent on testing for nursing homes, and approximately $1 billion on testing for uninsured people. The federal government also purchased and distributed delivered 175 million swabs and 193 million tubes of transport media.

    The US also delivered 4.3 million Abbott ID Now molecular tests, 53.7 million Abbott Binax Now rapid antigen tests to states, and 30 million Binax Now to places like nursing homes, tribes, and disaster relief organizations, according to a slide in Giroir's presentation.

    The US is distributing 120,000 tests through a K-12 school pilot program in Louisville, Kentucky; Los Angeles; New Orleans; Tulsa, Oklahoma; Rhode Island, and the District of Columbia. And, the federal program will distribute approximately 1.8 million tests in a strategic surveillance program with CDC in Colorado, North Dakota, Pennsylvania, Rhode Island, and Utah, as well as at the US Department of Veterans Affairs and with select tribal groups. The program will help "understand how we can best utilize point of care, particularly layered with point-of-care molecular [tests], like Cue, for diverse environments," he said, citing a recently authorized isothermal molecular, home-use test from Cue Health.

    Overall, the US has invested approximately $255 million in rapid antigen tests, $176 million in rapid molecular tests, and $570 million in lab-based tests through the NIH and BARDA. It also invested $155 million in increasing US swab production, $180 million in increasing reagent production, and $53 million in increasing US pipette tip production.

    For test procurement, Giroir said the US has spent more than $4.5 billion. A slide accompanying his talk listed $938 million for community-based testing sites, $760 million for BinaxNow rapid tests, $481 million for CUE's rapid molecular test, $198 million to IDNow, and $133 million for BD and Quidel rapid tests. The government also procured $659 in swabs and media, and spent $50 million on a national wastewater surveillance system, $400 million on solicitation for home tests, and $30 million on diagnostics data platform.

    Giroir repeatedly attributed the current shortage in testing supplies to manufacturing complexities for automated molecular diagnostics instruments. "Some of the most popular platforms just do not scale," he said.

    "It is a problem, it is an issue, and I can't fix it," he also said while telling attendees that this manufacturing bottleneck is "why you are running multiple platforms."

    In contrast, "There are certain platforms that there is basically an infinite supply of, like all the Thermo Fisher kinds of platforms, you can get as much of that as you want, [but] there are drawbacks to that," he said, adding, "That's really where we are until we get a more robust domestic supply chain. We talk to companies every single day, invest hundreds of millions of dollars, and that's where we are."

    For the future, the US needs more domestic manufacturing and a central supplies of reagents, he said. And, "We need to have the ability to expand selected technology and core reagents, not all of them," he added.

    Future preparedness also involves setting expectations for labs. "If you want [Thermo Fisher Scientific's] QuantStudio 5's and QuantStudio 7's, and you want Thermo Fisher platforms, we've got lots of them, they can make 60 million of those a month, but you are not going to scale some of the other tests, some of which are made abroad and we don't even have control over," Giroir said. "We are going to have to understand what you can get, accept it, and plan for supply realities."

    Another future direction Giroir proposed is more industry coordination. Currently, he has weekly calls with all major manufacturers of tests. "We know what their supply chain and production forecasts are, we know exactly what is coming out, we problem solve, we go over distribution, we know every EUA in development, when it is going to hit, and what it is going to do for the supply chain," he said. The team also has daily calls and frequent site visits with suppliers of swabs and pipette tips.

    While, the federal government cannot share very granular details of its insights into the supply chain, Giroir said his office could do better at sharing the general forecasts, but the bottom line is that the projects show "not a whole lot of growth" in the reagents for certain automated lab-based tests. 

    Moving forward, "We need to build a formal mechanism for collaboration, communication, and planning that can represent and incorporate multiple competing interests," he said, with a potential model being an electrical grid non-profit regulatory groups called the North American Electric Reliability Corporation (NERC) that aims to secure reliability of the US electric grid.

    Finally, Giroir said that a framework for laboratory-developed tests is also needed. He used his authority to order that FDA now review EUAs in a timely manner so that labs can get Public Readiness and Emergency Preparedness (PREP) Act coverage for liability. "The FDA is about 300 LDT reviews behind, so this is not going to happen very quickly, and we are trying to triage those as best as we can," he said, adding that this will hopefully begin in the first week of the new year.

    Giroir encouraged AACC attendees to contact him if they had any solutions to the shortages. "I promise you that there is no good idea that we don't try to uncover and work through. We are on the same team here and my job is to do as much as I can for you, and I will certainly continue to do that until Jan. 19," he said, referring to the end of the current presidential administration.

    This story first appeared in our sister publication 360Dx, which provides in-depth coverage of in vitro diagnostics and the clinical lab market.

     

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Data Points: Sticking with your resolutions
    Data Points: Sticking with your resolutions
    Want more diversity in clinical trials? Start with the researchers
    Want more diversity in clinical trials? Start with the researchers
    Sponsored Content
    Get Free Newsletters

    Sign up for free enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today

    The weekly magazine, websites, research and databases provide a powerful and all-encompassing industry presence. We help you make informed business decisions and lead your organizations to success.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS
    • Instagram

    Stay Connected

    Join the conversation with Modern Healthcare through our social media pages

    MDHC_Logotype_white
    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2021. Crain Communications, Inc. All Rights Reserved.
    • News
      • This Week's News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition
    • Insights
      • ACA 10 Years After
      • Best Practices
      • InDepth Special Reports
      • Innovations
    • Transformation
      • Patients
      • Operations
      • Care Delivery
      • Payment
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Award Programs
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Top 25 Minority Leaders
        • Top 25 Women Leaders
      • Nominate
      • Previous Award Programs
        • Excellence in Nursing Awards
        • Design Awards
        • Top 25 COOs in Healthcare
      • Other Award Programs
        • 100 Top Hospitals
        • ACHE Awards
    • Events
      • Conferences
        • Leadership Symposium
        • Healthcare Transformation Summit
        • Women Leaders in Healthcare Conference
        • Workplace of the Future Conference
        • Strategic Marketing Conference
        • Social Determinants of Health Symposium
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Minority Leaders Gala (2022)
        • Top 25 Women Leaders Gala
      • Webinars
      • COVID-19 Event Tracker
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing